08:44 AM EDT, 09/19/2024 (MT Newswires) -- CorMedix ( CRMD ) said Thursday that it has signed a commercial agreement with an unidentified dialysis operator to provide DefenCath to dialysis clinics in the US.

Under the deal, DefenCath will be available to adult patients with kidney failure receiving hemodialysis through a central venous catheter at more than 250 outpatient dialysis clinics, the company said.

CorMedix ( CRMD ) said it expects shipments of DefenCath, which reduces the incidence of catheter-related bloodstream infections, to begin in Q4.

Shares of CorMedix ( CRMD ) were up 2% in recent Thursday premarket activity.

Price: 7.39, Change: +0.14, Percent Change: +2.00